Xenetic Biosciences Statistics
Total Valuation
XBIO has a market cap or net worth of $8.93 million. The enterprise value is $2.46 million.
| Market Cap | 8.93M |
| Enterprise Value | 2.46M |
Important Dates
The last earnings date was Friday, August 7, 2026, before market open.
| Earnings Date | Aug 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
XBIO has 2.34 million shares outstanding. The number of shares has increased by 34.68% in one year.
| Current Share Class | 2.34M |
| Shares Outstanding | 2.34M |
| Shares Change (YoY) | +34.68% |
| Shares Change (QoQ) | +0.14% |
| Owned by Insiders (%) | 7.99% |
| Owned by Institutions (%) | 5.56% |
| Float | 1.89M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.58 |
| Forward PS | n/a |
| PB Ratio | 1.39 |
| P/TBV Ratio | 1.39 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.60 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.43
| Current Ratio | 7.43 |
| Quick Ratio | 7.23 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -47.04% and return on invested capital (ROIC) is -31.38%.
| Return on Equity (ROE) | -47.04% |
| Return on Assets (ROA) | -26.80% |
| Return on Invested Capital (ROIC) | -31.38% |
| Return on Capital Employed (ROCE) | -43.50% |
| Weighted Average Cost of Capital (WACC) | 16.09% |
| Revenue Per Employee | $1.63M |
| Profits Per Employee | -$1.24M |
| Employee Count | 2 |
| Asset Turnover | 0.53 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +25.74% in the last 52 weeks. The beta is 2.15, so XBIO's price volatility has been higher than the market average.
| Beta (5Y) | 2.15 |
| 52-Week Price Change | +25.74% |
| 50-Day Moving Average | 2.94 |
| 200-Day Moving Average | 2.74 |
| Relative Strength Index (RSI) | 77.93 |
| Average Volume (20 Days) | 71,666 |
Short Selling Information
The latest short interest is 11,313, so 0.48% of the outstanding shares have been sold short.
| Short Interest | 11,313 |
| Short Previous Month | 19,290 |
| Short % of Shares Out | 0.48% |
| Short % of Float | 0.60% |
| Short Ratio (days to cover) | 0.62 |
Income Statement
In the last 12 months, XBIO had revenue of $3.26 million and -$2.48 million in losses. Loss per share was -$1.19.
| Revenue | 3.26M |
| Gross Profit | 3.26M |
| Operating Income | -2.64M |
| Pretax Income | -2.48M |
| Net Income | -2.48M |
| EBITDA | n/a |
| EBIT | -2.64M |
| Loss Per Share | -$1.19 |
Balance Sheet
The company has $6.47 million in cash and no debt, with a net cash position of $6.47 million or $2.76 per share.
| Cash & Cash Equivalents | 6.47M |
| Total Debt | n/a |
| Net Cash | 6.47M |
| Net Cash Per Share | $2.76 |
| Equity (Book Value) | 6.07M |
| Book Value Per Share | 2.59 |
| Working Capital | 5.76M |
Cash Flow
| Operating Cash Flow | -2.31M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | -2.31M |
| FCF Per Share | -$0.99 |
Margins
Gross margin is 100.00%, with operating and profit margins of -81.01% and -75.91%.
| Gross Margin | 100.00% |
| Operating Margin | -81.01% |
| Pretax Margin | -75.91% |
| Profit Margin | -75.91% |
| EBITDA Margin | n/a |
| EBIT Margin | -81.01% |
| FCF Margin | n/a |
Dividends & Yields
XBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -34.68% |
| Shareholder Yield | -34.68% |
| Earnings Yield | -29.42% |
| FCF Yield | -27.49% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | 49.04% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 15, 2023. It was a reverse split with a ratio of 1:10.
| Last Split Date | May 15, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
XBIO has an Altman Z-Score of -36.1 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -36.1 |
| Piotroski F-Score | 3 |